{
    "2018-09-21": [
        [
            {
                "time": "2018-01-02",
                "original_text": "AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know",
                "features": {
                    "keywords": [
                        "Dips",
                        "Broader Markets"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Hagens Berman Alerts Investors in AbbVie Inc. (ABBV) to the Firm's Investigation of Possible Humira-Related Health Insurance Fraud and Disclosure Violations",
                "features": {
                    "keywords": [
                        "Investigation",
                        "Humira",
                        "Fraud",
                        "Disclosure Violations"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "CLASS ACTION UPDATE for AMPE, COCP, ABBV and SKX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "features": {
                    "keywords": [
                        "Class Action",
                        "Shareholders"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "Investigation",
                        "Claims",
                        "Losses"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Breakthrough",
                        "Therapy"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation of AbbVie Inc. - ABBV",
                "features": {
                    "keywords": [
                        "Investigation",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "CRON Stock Is a Long-term Play With Near-Term Challenges",
                "features": {
                    "keywords": [
                        "Long-term",
                        "Near-Term Challenges"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against AbbVie Inc. – ABBV",
                "features": {
                    "keywords": [
                        "Equity Alert",
                        "Securities Claims"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Drugmakers' Free Services Trigger Anti-Kickback Probe",
                "features": {
                    "keywords": [
                        "Free Services",
                        "Anti-Kickback",
                        "Probe"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy",
                "features": {
                    "keywords": [
                        "Positive CHMP Opinion",
                        "VENCLYXTO",
                        "Rituximab"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "How Do Drugs Compete Against Each Other?",
                "features": {
                    "keywords": [
                        "Drugs",
                        "Compete"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}